Intensity Therapeutics grants 11,000 stock options
Intensity Therapeutics, Inc. reported an option grant to Principal Accounting Officer John M. Wesolowski for 11,000 stock options to buy common stock at an exercise price of $4.90 per share.
Accepted by SEC EDGAR
Learn about SEC filing dates
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Intensity Therapeutics, Inc. reported an option grant to Principal Accounting Officer John M. Wesolowski for 11,000 stock options to buy common stock at an exercise price of $4.90 per share. The options vest in four equal annual installments beginning July 16, 2027 and expire July 16, 2036.
Insider Trade Summary
Grant/Award: 11,000 shares
Grant/Award
1 txn
Insider
Wesolowski John M
Role
Principal Accounting Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (right to buy Common Stock) F1 | 11,000 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (right to buy Common Stock) — 11,000 contracts (Direct)
Holdings Before and After:
Stock Option (right to buy Common Stock), 0 to 11,000 contracts (Direct)
Footnotes (1)
- F1. This option will vest, subject to the individual's continued service with Intensity Therapeutics, Inc., in four, equal, annual installments, beginning on July 16, 2027.
Key Figures
Options granted: 11,000 shares
Exercise price: $4.90 per share
Expiration date: July 16, 2036
+2 more
5 metrics
Options granted
11,000 shares
Stock options to buy common stock granted on July 16, 2026
Exercise price
$4.90 per share
Conversion or exercise price of the granted stock options
Expiration date
July 16, 2036
Expiration date of the 11,000 stock options
Vesting installments
4 equal annual installments
Vesting schedule beginning July 16, 2027, subject to continued service
Holdings after grant
11,000 derivative securities
Total stock options held directly by the reporting person following this grant
Key Terms
Stock Option (right to buy Common Stock), exercise price, vesting, derivative securities
4 terms
Stock Option (right to buy Common Stock) financial
"Security title reported as "Stock Option (right to buy Common Stock)""
exercise price financial
"Conversion or exercise price reported as 4.9000 per share for the option"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vesting financial
"This option will vest in four, equal, annual installments, beginning on July 16, 2027"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
derivative securities financial
"Derivative transaction type with 11,000 derivative securities reported after grant"
Financial contracts whose value is tied to the price or performance of another asset, such as a stock, bond, commodity, index, or currency; examples include options, futures and swaps. They matter to investors because they let you protect against price swings, bet on future moves or gain larger exposure with less upfront cash—like using a lever or insurance policy on an investment—so they can amplify gains and losses and help manage portfolio risk.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Intensity Therapeutics (INTS) report for John M. Wesolowski?
Intensity Therapeutics reported that Principal Accounting Officer John M. Wesolowski received a grant of 11,000 stock options on July 16, 2026. These derivative securities give him the right to buy common stock at a fixed exercise price in the future.
What are the key terms of the 11,000 stock options granted by INTS?
The grant covers 11,000 stock options with an exercise price of $4.90 per share. They are options on Intensity Therapeutics common stock, providing the right, but not the obligation, to purchase shares at that price before expiration.
What is the vesting schedule for John M. Wesolowski’s INTS stock options?
The option grant will vest in four equal annual installments, beginning on July 16, 2027. Vesting is subject to his continued service with Intensity Therapeutics, so unvested portions depend on ongoing employment with the company.
When do the newly granted Intensity Therapeutics (INTS) stock options expire?
The 11,000 stock options granted to John M. Wesolowski expire on July 16, 2036. He may exercise vested portions between the first vesting date in 2027 and this expiration date, subject to the award’s other terms and conditions.
How many derivative securities does John M. Wesolowski hold in INTS after this grant?
Following the transaction, John M. Wesolowski holds 11,000 derivative securities (stock options) directly. This total reflects the newly granted options reported, with no additional derivative holdings shown in this particular Form 4 filing.
Was the INTS insider option grant reported as part of a Rule 10b5-1 trading plan?
No. The Form 4 indicates the Rule 10b5-1 checkbox is not marked, meaning the reported option grant was not affirmed as made under a Rule 10b5-1 pre-arranged trading plan for this insider transaction.
AI-generated analysis. How Rhea-AI works. Not financial advice.
